TOP TEN perturbations for 206248_at (Homo sapiens)

Organism: Homo sapiens
Gene: 206248_at
Selected probe(set): 226101_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 206248_at (226101_at) across 5961 perturbations tested by GENEVESTIGATOR:

medulloblastoma study 1 / non-tumor brain tissue

Relative Expression (log2-ratio):-3.607769
Number of Samples:17 / 9
Experimental medulloblastoma study 1
Primary tumor tissue sample from the infratentorial brain of pediatric patients with classical medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)

Relative Expression (log2-ratio):3.4551544
Number of Samples:2 / 2
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 6 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART).

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):3.446743
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):-3.3024006
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):3.2555523
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-3.1676455
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-3.1189222
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

atypical teratoid/rhabdoid tumor study 1 / non-tumor brain tissue

Relative Expression (log2-ratio):-3.0294294
Number of Samples:20 / 9
Experimental atypical teratoid/rhabdoid tumor study 1
Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT).
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):3.0270014
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

brain tumor study 1 (medulloblastoma) / normal brain tissue

Relative Expression (log2-ratio):-2.9818287
Number of Samples:22 / 12
Experimental brain tumor study 1 (medulloblastoma)
Primary tumor tissue sample from the brain of patients with medulloblastoma.
Control normal brain tissue
Histologically normal and non-neoplastic tissue sample from different brain anatomical sites of patients with primary brain tumors.